Ocugen (OCGN) said Monday that two-year data from a phase 1/2 trial showed that OCU400 improved visual function in children and adults with retinitis pigmentosa.
The company said treatment with the drug candidate showed "meaningful" improvement of 2-line gain, or 10 letters on ETDRS chart, in low-luminance visual acuity.
The effect of the treatment was "statistically significant" in all subjects regardless of mutation at two years, the company added.
Ocugen said it is conducting a phase 3 trial and expects to submit a biologics license application in H1 2026 as planned.
The company's shares were falling 4.4% in recent trading.
Price: 0.75, Change: -0.03, Percent Change: -4.39
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.